July 1, 2025 Where to Rent Stable Turkish Datacenter Proxies?
June 24, 2025 PayPal’s News Analysis—A Short and Medium-Term Price Forecast
June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
Bavarian Nordic (BVNRY) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: July 7, 2025 (23:25)
Sector: HealthcareThe share price of Bavarian Nordic A/S (BVNRY) now
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 1 (1/0/0) |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: Na |
Are you interested in Bavarian Nordic A/S stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Bavarian Nordic stock price in 2025, 2026, 2027. How much will one Bavarian Nordic share be worth in 2025 - 2027?
When should I take profit in Bavarian Nordic stock? When should I record a loss on Bavarian Nordic stock? What are analysts' forecasts for Bavarian Nordic stock? What is the future of Bavarian Nordic stock? We forecast Bavarian Nordic stock performance using neural networks based on historical data on Bavarian Nordic stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Bavarian Nordic stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Bavarian Nordic shares. This happens once a day.
Historical and forecast chart of Bavarian Nordic stock
The chart below shows the historical price of Bavarian Nordic stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Bavarian Nordic stock price can be found in the table below.
Long-term forecasts by years.
Bavarian Nordic A/S Analysts predictions review

Bavarian Nordic (BVNRY) demonstrates strong growth potential driven by its innovative vaccine pipeline and strategic partnerships that enhance operational efficiency and market access. Emerging products in oncology and infectious diseases are key revenue drivers, supported by industry trends and rising demand. Expansion into respiratory vaccines, coupled with diversified revenue streams, mitigates risks from cyclical product demand. While liquidity pressures exist due to investment in R&D and partnerships, stable cash flow and cost optimization bolster financial resilience. Government funding for public health initiatives adds to its defensive moat but remains a variable risk factor.

Bavarian Nordic: Undervalued Stock Poised for Growth Amid Promising 2025 Forecast

Bavarian Nordic (BVNRY) is reportedly attracting attention due to its current undervaluation relative to industry peers, presenting an opportunity for value-oriented investors. The company's strong pipeline of innovative vaccine products and its focus on addressing unmet medical needs suggest potential for consistent revenue growth.
Strategic partnerships have bolstered Bavarian Nordic's prospects, enhancing operational efficiency and expanding market access. Analyst Array emphasizes how these collaborations could mitigate risks associated with scaling production and entry into new markets.
Forward Looking Growth Drivers
The 2025 outlook, detailed in the article, highlights significant revenue expansion underpinned by demand for emerging products in oncology and infectious disease vaccines. This growth potential aligns with broader industry trends and could strengthen investor confidence in the stock over time.
Operational metrics, including cost optimization and margin improvements, position BVNRY as a pragmatic long-term investment choice. These indicators suggest management's strategic focus on bolstering profitability could provide resilience against macroeconomic headwinds.

Positioning Bavarian Nordic for Growth: Vaccine Strengths and Revenue Projections for 2025

Bavarian Nordic's robust vaccine portfolio is a central driver of its growth outlook, underpinned by its recognized expertise in immunology and infectious disease prevention. The company's advancements in key programs, such as its monkeypox and smallpox vaccines, solidify its competitive position, particularly in securing government and institutional contracts. According to the author, this provides a strong defensive moat within an expanding global market for preventive health solutions.
The projected revenue expansion by 2025 is grounded in strategic product launches and commercialization efforts, especially within the RSV and influenza markets. These high-growth therapeutic areas offer significant upside potential as Bavarian Nordic leverages its pipeline to gain market share, supported by increasing demand for innovative respiratory vaccines.
Revenue Diversification and Long-Term Drivers
Partnership agreements with large-cap pharmaceutical companies enhance the company's profile and mitigate risks associated with single-product dependency. Such collaborations reinforce Bavarian Nordic's research and development capabilities, enabling it to focus resources on high-yielding projects identified by the author as essential to future growth.
Macroeconomic factors, particularly government funding for public health initiatives, play a vital role in the company's trajectory. Any shifts in funding priorities could affect the valuation, but the current trend supports sustained investment in its product portfolio.

Bavarian Nordic: Diversification Drives Stability Amid Waning Mpox Demand

Bavarian Nordic's recent performance reveals a strategic shift, as the demand for its Mpox vaccine subsides. This decline in Mpox-related revenue highlights the company's vulnerability to overly specialized product reliance in the near term. However, the company's proactive measures to diversify its portfolio, particularly through advancements in infectious disease and oncology vaccines, significantly strengthen its long-term growth prospects. According to the author, this diversification could mitigate revenue volatility stemming from cyclical demand for its legacy products.
Portfolio Expansion as a Growth Catalyst
Another key factor discussed is Bavarian Nordic's recent partnerships and acquisitions aimed at enhancing its R&D pipeline. These collaborations position the company to stay competitive within the biopharmaceutical landscape and align with an industry-wide trend toward innovation through external synergies. While such investments require upfront capital, the author suggests that their long-term payoff is likely to outweigh short-term liquidity pressures.
Lastly, Bavarian Nordic’s financial health remains a crucial element of the analysis. The company’s ability to maintain stable operational cash flow, despite a revenue shift, underscores management's effectiveness in navigating market transitions. This stability serves as a foundation for executing its growth strategy, though investors should monitor any indications of rising leverage that could adversely affect shareholder value.
BVNRY's strategic focus on expanding Jynneos production is a critical factor for the company's growth as the global demand for vaccines addressing health emergencies continues to rise. By positioning itself as a key supplier in this niche, Bavarian Nordic could capture significant value from global immunization initiatives, a sentiment highlighted by the author as a core advantage for shareholders.
Strengthened Market Position Through Collaboration and Innovation
The company's recent collaborations with government health agencies and multinational organizations provide not only robust revenue streams but also an enhanced reputation within the healthcare sector. According to the author, these partnerships could significantly mitigate financial risks tied to unpredictable market conditions and demonstrate a long-term commitment to innovation.
On the operational front, Bavarian Nordic has showcased resilience in navigating challenges tied to manufacturing scalability amidst increased demand. The author highlights that successful execution of supply chain optimization will be a decisive factor in determining the company's ability to sustain momentum and meet stakeholder expectations.
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Bavarian Nordic daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul 09 | 8.72 | 8.62 | 8.85 | 2.63 |
Jul 10 | 8.76 | 8.45 | 8.98 | 6.32 |
Jul 11 | 8.58 | 8.37 | 8.87 | 6.00 |
Jul 12 | 8.59 | 8.29 | 8.92 | 7.56 |
Jul 13 | 8.46 | 8.30 | 8.60 | 3.67 |
Jul 14 | 8.83 | 8.50 | 9.11 | 7.17 |
Jul 15 | 8.77 | 8.60 | 8.90 | 3.57 |
Jul 16 | 8.85 | 8.52 | 8.96 | 5.19 |
Jul 17 | 8.49 | 8.38 | 8.61 | 2.74 |
Jul 18 | 8.42 | 8.23 | 8.70 | 5.68 |
Jul 19 | 8.04 | 7.75 | 8.15 | 5.13 |
Jul 20 | 8.44 | 8.12 | 8.65 | 6.44 |
Jul 21 | 8.71 | 8.61 | 8.93 | 3.74 |
Jul 22 | 8.69 | 8.42 | 8.82 | 4.69 |
Jul 23 | 9.11 | 8.90 | 9.39 | 5.58 |
Jul 24 | 9.01 | 8.87 | 9.27 | 4.57 |
Jul 25 | 9.43 | 9.18 | 9.79 | 6.68 |
Jul 26 | 9.51 | 9.28 | 9.63 | 3.74 |
Jul 27 | 9.16 | 9.00 | 9.31 | 3.46 |
Jul 28 | 8.88 | 8.72 | 8.97 | 2.85 |
Jul 29 | 9.06 | 8.76 | 9.19 | 4.86 |
Jul 30 | 9.00 | 8.90 | 9.19 | 3.29 |
Jul 31 | 8.98 | 8.79 | 9.12 | 3.83 |
Aug 01 | 9.36 | 9.00 | 9.56 | 6.24 |
Aug 02 | 9.18 | 8.83 | 9.41 | 6.55 |
Aug 03 | 9.34 | 9.24 | 9.49 | 2.73 |
Aug 04 | 9.12 | 8.89 | 9.28 | 4.41 |
Aug 05 | 9.08 | 8.79 | 9.28 | 5.53 |
Aug 06 | 9.23 | 9.07 | 9.33 | 2.80 |
Aug 07 | 9.00 | 8.67 | 9.29 | 7.11 |
Bavarian Nordic Daily Price Targets
Bavarian Nordic Stock Forecast 07-09-2025.
Forecast target price for 07-09-2025: $8.72.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 2.562%.
Pessimistic target level: 8.62
Optimistic target level: 8.85
Bavarian Nordic Stock Forecast 07-10-2025.
Forecast target price for 07-10-2025: $8.76.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 5.948%.
Pessimistic target level: 8.45
Optimistic target level: 8.98
Bavarian Nordic Stock Forecast 07-11-2025.
Forecast target price for 07-11-2025: $8.58.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 5.660%.
Pessimistic target level: 8.37
Optimistic target level: 8.87
Bavarian Nordic Stock Forecast 07-12-2025.
Forecast target price for 07-12-2025: $8.59.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 7.033%.
Pessimistic target level: 8.29
Optimistic target level: 8.92
Bavarian Nordic Stock Forecast 07-13-2025.
Forecast target price for 07-13-2025: $8.46.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 3.538%.
Pessimistic target level: 8.30
Optimistic target level: 8.60
Bavarian Nordic Stock Forecast 07-14-2025.
Forecast target price for 07-14-2025: $8.83.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 6.689%.
Pessimistic target level: 8.50
Optimistic target level: 9.11
BVNRY (BVNRY) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul. | 9.05 | 7.64 | 10.01 | 23.69 |
Aug. | 9.23 | 8.61 | 10.25 | 16.04 |
Sep. | 8.83 | 7.93 | 9.36 | 15.28 |
Oct. | 7.38 | 6.26 | 8.25 | 24.15 |
Nov. | 6.10 | 5.24 | 6.51 | 19.48 |
Dec. | 6.30 | 5.42 | 6.76 | 19.78 |
Bavarian Nordic forecast for this year
Bavarian Nordic Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $9.0528. Pessimistic: $7.64. Optimistic: $10.01
Bavarian Nordic Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $9.23386. Pessimistic: $8.61. Optimistic: $10.25
Bavarian Nordic Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $8.82757. Pessimistic: $7.93. Optimistic: $9.36
Bavarian Nordic Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $7.37985. Pessimistic: $6.26. Optimistic: $8.25
Bavarian Nordic Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $6.09575. Pessimistic: $5.24. Optimistic: $6.51
Bavarian Nordic Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $6.30301. Pessimistic: $5.42. Optimistic: $6.76
Bavarian Nordic (BVNRY) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 6.74 | 6.20 | 7.32 | 15.29 |
Feb | 6.65 | 5.94 | 7.33 | 18.87 |
Mar | 6.34 | 6.05 | 6.86 | 11.83 |
Apr | 6.32 | 6.05 | 6.77 | 10.63 |
May | 6.76 | 6.29 | 7.10 | 11.43 |
Jun | 7.34 | 7.02 | 8.47 | 17.16 |
Jul | 8.63 | 7.25 | 9.27 | 21.79 |
Aug | 9.57 | 8.90 | 10.16 | 12.43 |
Sep | 11.40 | 10.63 | 12.25 | 13.22 |
Oct | 13.62 | 11.85 | 14.60 | 18.84 |
Nov | 13.94 | 12.88 | 15.70 | 17.94 |
Dec | 16.23 | 15.58 | 18.79 | 17.10 |
Bavarian Nordic (BVNRY) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 15.71 | 13.73 | 17.60 | 21.96 |
Feb | 16.12 | 14.64 | 17.51 | 16.39 |
Mar | 13.19 | 12.42 | 14.79 | 16.04 |
Apr | 14.16 | 12.26 | 14.98 | 18.15 |
May | 12.69 | 11.75 | 13.25 | 11.30 |
Jun | 15.02 | 14.06 | 16.68 | 15.68 |
Jul | 15.05 | 13.52 | 15.93 | 15.12 |
Aug | 17.43 | 14.75 | 18.97 | 22.24 |
Sep | 18.93 | 18.17 | 21.77 | 16.52 |
Oct | 15.52 | 13.23 | 17.98 | 26.43 |
Nov | 13.78 | 12.08 | 14.94 | 19.19 |
Dec | 15.11 | 13.78 | 17.07 | 19.29 |
Bavarian Nordic information and performance
N/A
Market capitalization of the Bavarian Nordic A/S is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BVNRY shares in the company outstanding by the market price of one share.
EBITDA of Bavarian Nordic is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
FAQ (Frequently Asked Questions about Bavarian Nordic Stock)
Should I Buy Bavarian Nordic Shares in 2025 year?
Does Bavarian Nordic pay dividends?
Which economic sector do Bavarian Nordic's shares belong to?
Which other securities belong to the same sector as Bavarian Nordic's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.